Tech Company Financing Transactions
Apexian Pharmaceuticals Funding Round
Elevate Ventures participated in a Series A capital raise for Apexian Pharmaceuticals. The round was announced by the company on 11/30/2017.
Transaction Overview
Company Name
Announced On
11/30/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Elevate Ventures (Chris LaMothe)
Proceeds Purpose
Proceeds will be used to initiate their phase 1 clinical study for APX3330, a novel first-in-class oral treatment for patients with cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20 N. Meridian Guaranty Bldg. 801
Indianapolis, IN 46204
USA
Indianapolis, IN 46204
USA
Phone
Website
Email Address
Overview
Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Broecker
Chief Medical Officer
Richard Messmann
Chief Operating Officer
Roger Miller
Chief Scientific Officer
Mark Kelley
VP - Operations
Jan Elkins
VP - R & D
James Wikel
VP - Regulatory Affairs
William Current
VP - Regulatory Affairs
Roberta Smithey
Browse more venture capital transactions:
Prev: 11/30/2017: Artesian Solutions venture capital transaction
Next: 11/30/2017: Lumiata venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs